<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199510</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-09-05</org_study_id>
    <nct_id>NCT01199510</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of SYSTANE速 ULTRA in Patients Scheduled for Cataract Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of FID 112903 (SYSTANE ULTRA速
      Lubricating Drops) plus standard of care to standard of care alone, in subjects with a
      history of intermittent eye irritation or dryness related to environmental factors and
      scheduled for routine cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Comfort</measure>
    <time_frame>30 days</time_frame>
    <description>Ocular comfort will be reported by the patient on a questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Dry Eye</condition>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Standard of Care plus FID 112903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYSTANE速 ULTRA Lubricant Eye Drops dosed 4 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post Cataract Standard of Care Regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FID 112903 (SYSTANE速 ULTRA Lubricant Eye Drops) plus standard of care</intervention_name>
    <description>Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively</description>
    <arm_group_label>Standard of Care plus FID 112903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Post Cataract Surgery Standard of Care</description>
    <arm_group_label>Standard of Care only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age

          -  Patients must be seeking routine cataract extraction with monofocal intraocular lens
             implantation

        Exclusion Criteria:

          -  Patients for whom both eyes do not meet all inclusion criteria and either eye meets
             any exclusion criteria.

          -  Patients cannot have a history of hypersensitivity to any component of FID 112903.

          -  Patients cannot have previous intraocular or corneal surgery or any planned within 30
             days.

          -  Patients cannot use any ocular medications other than test article and standard of
             care post-op medications in past 14 days or during study.

          -  Patients cannot be on chronic systemic corticosteroid or other immunosuppressive
             therapy.

          -  Patients cannot have a history of steroid-responsive rise in intraocular pressure,
             glaucoma, or preoperative Intraocular pressure &gt;25 millimeters mercury in either eye.

          -  Patients cannot have a history and/or current evidence of the following: clinically
             significant corneal scarring, blepharitis or macular pathology in either eye, Herpes
             zoster or Herpes simplex keratitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>http://www.escrs.org/abstracts/details.asp?confid=9&amp;sessid=372&amp;type=free&amp;paperid=14295</citation>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

